Answers are grounded in this paper and cite their sources.
Observational study demonstrates infrequent therapy interruptions despite common hepatic test disturbances in fungal infection cohorts, indicating viable tolerability.
This analysis of 116 isavuconazole therapy courses shows that hepatic test disturbances (HTDs) were relatively frequent (29% of cases) but rarely led to treatment interruption (5%). Importantly, patients with baseline HTDs, including those attributed to a first-line triazole, did not exhibit a higher risk of subsequent HTD under isavuconazole therapy.
No takes yet. Share an insight, caveat, or question.
Couchepin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: